The quarter was mixed against expectations, not a clean beat. Kura reported a smaller-than-expected revenue line but a better-than-expected loss: total revenue was $20.9 million versus published consensus of roughly $21.7 million, while the $0.77 per-share loss was narrower than the approximately $0.90 consensus loss.
| Metric | Q2 2026 | Comparison / expectation |
|---|---|---|
| Net product revenue | $9.1M | Up 57% from Q1 2026 (Financial Highlights) |
| New patient starts | ~115 | Up 35% from Q1 2026 (Commercial highlights) |
| Total prescriptions | >250 | Up 59% from Q1 2026 (Commercial highlights) |
| Total revenue | $20.9M | $15.3M in Q2 2025; ~$21.7M consensus (Statements of Operations Data) |
| Net loss per share | $(0.77) | $(0.75) in Q2 2025; ~$0.90 loss consensus (Statements of Operations Data) |
| Cash, equivalents and short-term investments | $519.0M | $667.2M at December 31, 2025 (Balance Sheet Data) |
KOMZIFTI's commercial trajectory was the strongest part of the filing. Product revenue reached $9.1 million, while new patient starts rose 35% sequentially to approximately 115 and total prescriptions increased 59% to more than 250. The company also claimed majority share of new patient starts in the relapsed/refractory NPM1-mutated AML menin-inhibitor class after only two full launch quarters (Commercial highlights). The direction of improving uptake was already known; the magnitude and claimed early class leadership are the new information.
The revenue miss was driven by the less durable collaboration stream, not a collapse in product demand. Collaboration revenue declined to $11.8 million from $15.3 million a year earlier, partially offsetting the $9.1 million of new product revenue (Statements of Operations Data). That makes the headline revenue shortfall less damaging to the launch thesis, but it still means the reported top line did not clear the market's published bar.
The expense profile was controlled enough to produce an EPS beat, but losses remain substantial. Research and development spending was nearly flat year over year at $61.9 million, while selling, general and administrative expense rose to $31.8 million as commercialization scaled (Statements of Operations Data). Net loss widened modestly to $68.3 million from $66.1 million, so the narrower per-share loss appears more favorable than the underlying absolute-loss trend because of share-count and other below-operating-line factors.
The strategic picture improved, but the biggest value drivers remain unproven future expansions. Long-term frontline AML data showed high response rates and 12-month overall survival in early-stage combination cohorts, while darlifarnib produced encouraging response signals in renal-cell and KRAS-mutated tumors (KOMET-007 data; FIT-001 data). These are supportive clinical signals, not registrational outcomes. The next meaningful test is the planned 2H 2026 frontline and combination-data flow.
Funding risk looks manageable through the next major AML milestone, though cash is being consumed quickly. Cash and short-term investments fell by $148.2 million from year-end to June 30, 2026, but Kura expects another $180 million in collaboration payments and says resources should fund the ziftomenib AML program through topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028 (Balance Sheet Data; Anticipated Milestones). Net: commercial execution and EPS were better than feared, but the modest revenue miss keeps the overall filing in line rather than positive.
Read the original 8-K on SEC EDGAR ↗